Tranexamic Acid in Nasal Mohs Reconstruction

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Epinephrine; Epinephryl borate; Lidocaine; Racepinephrine; Tranexamic Acid

Criteria

Inclusion Criteria:

1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.

2. No other facial plastic procedure or sinus surgery performed simultaneously.

3. Lack of all the below exclusion criteria.

Exclusion Criteria:

1. Known allergy to TXA

2. Intracranial bleeding

3. Known defective color vision

4. History of venous or arterial thromboembolism

5. History of coagulation disorder

6. Active thromboembolic disease

7. Severe renal impairment (diagnosis of chronic kidney disease)

8. History of acute myocardial infarction

9. History of stroke

10. History of seizure

11. History of liver failure

12. Preoperative lab results indicating thrombocytopenia (platelets <150,000), increased bleeding risk (PT over 45, INR over 1.2).